Dow Jones
39.671,04 -201,95 (-0,51%) Nasdaq
16.801,54 -31,08 (-0,18%) Nikkei 225
39.066,12 +449,02 (+1,16%) EUR/USD
1,0833 +0,0006 (+0,05%) Bitcoin EUR
64.188,07 +88,17 (+0,14%) CMC Crypto 200
1.511,94 -14,47 (-0,95%)
Clearside Biomedical, Inc. (CLSD)
Dopo ore:
| Chiusura precedente | 1,4900 |
| Aperto | 1,4800 |
| Denaro | 1,3200 x 100 |
| Domanda | 1,3800 x 200 |
| Min-Max giorno | 1,3200 - 1,5100 |
| Intervallo di 52 settimane | 0,6500 - 2,1200 |
| Volume | |
| Media Volume | 398.300 |
| Capitalizzazione | 100,887M |
| Beta (mensile su 5 anni) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,5500 |
| Prossima data utili | 12 ago 2024 - 16 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 5,33 |
GlobeNewswireClearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting
- Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – - ODYSSEY Phase 2b Clinical Trial Enrollment is On Track with Data Expected in Q3 2024 - ALPHARETTA, Ga., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that key data from the Phase 1/2a OASIS clinical trial wer
- GlobeNewswire
Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China
- Continued Progress in the Global Development and Commercialization of XIPERE® (known as ARCATUS® in China) - ALPHARETTA, Ga., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that Arctic Vision, Clearside’s partner, has successfully completed enrollment in its Phase 3 randomized, double-blind, placebo-controlled clinical tri
- GlobeNewswire
Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit
ALPHARETTA, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Charles A. Deignan, Chief Financial Officer, will participate in a panel discussion at the JonesTrading 2023 Healthcare Summit. The panel, entitled, All About Eyes: Paradigm Shifting Therapeutic Innovations in Ophthalmology will take place on October
